Every article, report, and earnings note where ATTO appears.
Attovia's insider signal is bullish, but the cleanly supported figure is $10.29 million rather than the touted $20.57 million. The smaller number still matters because it arrived alongside a roughly $289 million IPO and a lead asset already tested in humans.
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.
Atento S.A. is expected to list on NASDAQ on 2026-08-05 in a 12,500,000-share offering priced at $15.00 to $17.00 per share. The implied market cap is $244,375,000 if priced at the midpoint. The bull case is a scaled CRM/BPO platform with AI and nearshore delivery; the bear case is that the company already appears to be a long-established public issuer, so investors should watch closely for confirmation of what is actually being offered.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ATTO ReportCancel anytime